203 related articles for article (PubMed ID: 12293274)
1. German court lifts OC prescription ban.
Contracept Technol Update; 1998 Mar; 19(3):41-2. PubMed ID: 12293274
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism and desogestrel- or gestodene-containing combination oral contraceptives: what are the facts?
Contracept Rep; 1996 Apr; 7(1):3-6. PubMed ID: 12320047
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptives and venous thromboembolism: consensus conference statement.
Dialogues in Contraception Consensus Conference (1995: Chicago)
Dialogues Contracept; 1996; ():1-8. PubMed ID: 12320455
[TBL] [Abstract][Full Text] [Related]
4. Oral contraceptive pills and the risk of venous thromboembolism.
Prog Hum Reprod Res; 1996; (39):2-3. PubMed ID: 12292198
[TBL] [Abstract][Full Text] [Related]
5. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
6. Estrogen dose in oral contraceptives: FDA committee examines safety and utility of 50 mcg estrogen OCs.
Contracept Rep; 1994 Mar; 5(1):10-3. PubMed ID: 12287738
[TBL] [Abstract][Full Text] [Related]
7. 2 methods for prescribing third-generation OCs.
Contracept Technol Update; 1997 Dec; 18(12):148-9. PubMed ID: 12348220
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of venous thromboembolic disease and OC use.
Ory HW
Dialogues Contracept; 1996; 5(1):4-7, 10. PubMed ID: 12347722
[TBL] [Abstract][Full Text] [Related]
9. Warnings on venous thromboembolism risks may have been premature. New data may lead to change in use of third-generation OCs.
Contracept Technol Update; 1997 Dec; 18(12):145-8. PubMed ID: 12348219
[TBL] [Abstract][Full Text] [Related]
10. Researchers can now investigate long-term effects of OCs on cancer.
Rubin GL; Peterson HB
Contracept Technol Update; 1985 Jan; 6(1):7-12. PubMed ID: 12279918
[TBL] [Abstract][Full Text] [Related]
11. Oral contraceptives and venous thromboembolism.
Paul C
N Z Med J; 1996 Nov; 109(1033):413-5. PubMed ID: 8941290
[TBL] [Abstract][Full Text] [Related]
12. [Combined contraceptives and cardiovascular risk].
Belaisch J; Hommais-loufrani B
Contracept Fertil Sex (Paris); 1987 Dec; 15(12 Suppl):1-8. PubMed ID: 12315199
[TBL] [Abstract][Full Text] [Related]
13. [Vascular disease and hormonal treatment--epidemiology].
Vessey MP
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):121-6. PubMed ID: 12280197
[TBL] [Abstract][Full Text] [Related]
14. Another pill scare -- should we audit its impact?
Bromham DR
Audit Unit News; 1996 Jan; 1(4):2-3. PubMed ID: 12346948
[TBL] [Abstract][Full Text] [Related]
15. Coagulation and thrombosis with OC use: physiology and clinical relevance.
Comp PC
Dialogues Contracept; 1996; 5(1):1-3. PubMed ID: 12347721
[TBL] [Abstract][Full Text] [Related]
16. A perspective on the concept of "risk".
Westhoff CL
Dialogues Contracept; 1996; 5(1):8-9. PubMed ID: 12347723
[TBL] [Abstract][Full Text] [Related]
17. Oral contraceptive risks: a realistic appraisal.
Bressler R; Durand JL
Drug Ther (NY); 1979 Oct; 9(10):81-95. PubMed ID: 12279276
[TBL] [Abstract][Full Text] [Related]
18. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
Farmer RD; Lawrenson RA
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S78-86. PubMed ID: 9753314
[TBL] [Abstract][Full Text] [Related]
19. The misunderstood pill: thirty years of testing and development have reduced pill's major, minor side effects.
United States. Centers for Disease Control CDC. Advisory Committee on Immunization Practices
Netw Res Triangle Park N C; 1986; 7(4):1-5. PubMed ID: 12341093
[TBL] [Abstract][Full Text] [Related]
20. Estrogen component of OCs.
Kaunitz AM; Ory H
Dialogues Contracept; 1997; 5(4):1-6. PubMed ID: 12293158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
